Rochester is one of four NIH-sponsored centers that aims to produce tissue-on-chip devices as FDA-qualified drug development tools.
The University of Rochester will house a new national center focused on using tissue-on-chip technology to develop drugs and reduce the need for animal trials rapidly. The National Institutes of Health awarded a $7.5 million grant to establish the Translational Center for Barrier Microphysiological Systems (TraCe-bMPS) at Rochester in partnership with Duke University.
‘CLINICAL TRIALS ON CHIP’: The chips produced by TraCe-bMPS will feature photonic biosensors crafted by Benjamin Miller, a Dean’s Professor of Dermatology at Rochester with joint appointments in biomedical engineering, biochemistry and biophysics, optics, and materials science. Image credit: University of Rochester photo / Benjamin Miller Lab
The center aims to develop five Food and Drug Administration–qualified drug development tools related to study barrier functions in disease—interfaces in tissue that are critical for the progression of infection, cancer, and many autoimmune disorders. Over the five-year grant, the researchers will create drug development tools specifically related to central nervous system disorders, fibrosis, musculoskeletal autoimmune disease, sepsis, and osteomyelitis.
The TraCe-bMPS scientists will create the drug development tools using microphysiological systems—small chips with ultrathin membranes of human cells. They will be built using the modular, mass-producible µSiM chips pioneered by center director James McGrath, the William R. Kenan Jr. Professor of Biomedical Engineering.
McGrath says that testing drugs on µSiM chips can lead to fewer animal trials. And because researchers will be studying the drugs’ effects on human cells, they may also help overcome some of the critical differences between testing on humans and animals.
ALL MICROPHYSIOLOGICAL SYSTEMS GO: Researchers at the University of Rochester’s new Translational Center for Barrier Microphysiological Systems (TraCe-bMPS) develop drug development tools using the modular, mass-producible µSiM chips pictured here and pioneered by center director James McGrath, the William R. Kenan Jr. Professor of Biomedical Engineering. (University of Rochester photo / J. Adam Fenster)
“Drug discovery is moving into an era where fewer animals are used to test for safety and efficacy,” says McGrath. “Instead, more screening will be done on tissue chips that pattern human cells to mimic human tissue and disease. Our chips are designed to provide the higher throughput and more reliable indications that pharmaceutical companies need to get their drugs approved for clinical trials and use by patients.”
Hani Awad, the Donald and Mary Clark Distinguished Professor in Orthopaedics and a professor of biomedical engineering, will serve as the associate director for development. He says Congress passing the FDA Modernization Act 2.0 in 2022 made the center possible and that the team is excited to help shape the future of drug development.
“The timing could not be more perfect,” says Awad. “As a biomedical engineer and scientist, I find the elegant fusion of engineering and biology inherent in the design and validation of these tissue chips as disease models and drug-testing platforms to be one of my most rewarding professional pursuits. I can’t wait to see what this team will develop over the next five years, and beyond.”
CHIPPING IN: Biomedical engineering PhD students Danial Ahmad (L) and Molly McCloskey assemble fixtures used to guide components and membrane chips to create the modular µSiM tissue chip platform, featuring an ultrathin nanomembrane. (University of Rochester photo / J. Adam Fenster)
The chips will feature photonic biosensors crafted by Benjamin Miller, a Dean’s Professor of Dermatology at Rochester with joint appointments in biomedical engineering, biochemistry and biophysics, optics, and materials science. Miller, the center’s associate director for resources, says the center is the culmination of years of research and collaboration.
“Getting our devices qualified by the FDA as drug development tools will mean that we’re a step closer to doing ‘clinical trials on chip’ with fully human models, increasing the likelihood of a drug candidate being successful when it actually gets to human clinical trials,” says Miller. “This is also a great opportunity to build an interdisciplinary training environment for our students and expand a collaboration with my colleagues that has been very productive.”
Joan Adamo, director of the Office of Regulatory Support at the University of Rochester Medical Center’s Clinical and Translational Science Institute, will serve as associate director and prepare all submissions to the FDA for qualification. Adamo says she sees the ambitious program having far-reaching implications.
“This unique program involves close collaboration with the FDA through a series of qualification steps—a critical aspect to addressing unmet needs,” says Adamo. “I am looking forward to working closely with the agency and our collaborators on this regulatory science project. We will achieve qualification of these vital drug development tools, which will accelerate research conducted at URMC and be shared with other academic health centers and industry programs.”
Source: University of Rochester